Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising secondary results and a positive safety profile for the 60 mg dose. ACADIA will continue late-stage trials focusing on this dose, reflecting cautious short-term but optimistic long-term prospects.
ACADIA Pharmaceuticals (ACAD) is trading at USD 22.81 with a 10.30% drop as of Sep 25, 2026 02:01 WIB on Pluang, closely mirroring the article's noted 10.5% stock decline after Citigroup cut its price target. Despite the setback, Pluang investors show strong confidence with 93% buy orders. Meanwhile, Citigroup (C) itself is slightly up by 0.39% at USD 132.48, indicating steady market interest in the financial sector.
Acadia Pharmaceuticals reported phase 2/3 trial results for remlifanserin in Alzheimer’s disease psychosis, where the high dose failed to reach statistical significance but indicated positive efficacy trends. Although the drug showed a clean safety p...
Acadia Pharmaceuticals' shares fell over 9% following mixed Phase 2 trial results for remlifanserin, a drug for Alzheimer's disease psychosis. The 60 mg dose showed some improvement in hallucinations and delusions but narrowly missed statistical sign...
